<DOC>
	<DOCNO>NCT02093260</DOCNO>
	<brief_summary>To Asses Immunogenicity Safety Flubio ( Influenza HA ) Vaccine Infants Children ( Bridging Study )</brief_summary>
	<brief_title>Immunogenocity Safety Flubio ( Influenza HA ) Vaccine Infants Children ( Bridging Study )</brief_title>
	<detailed_description>Too see percentage subject HI titer &gt; = 1:40 , 28 day two dos infant child ( 6 months-8 year old ) one dose child 9-11 year old strain .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Parents inform properly regard study sign informed consent form Parents commit comply instruction investigator schedule trial Subjects concomitantly enrol schedule enrol another trial Evolving mild , moderate , severe illness , especially infectious disease fever ( axillary temperature &gt; =37oC ) Known history allergy egg and/or chicken protein component vaccine Known history uncontrolled coagulopathy blood disorder contraindicate intramuscular injection Subject receive treatment likely alter immune response previous 4 week ( intravenous immunoglobulin , bloodderived product long term corticotherapy ( &gt; 2 week ) ) . Any abnormality chronic disease justify investigator might interfere assessment trial objective . Subjects immunized influenza vaccine within 1 year Subjects receive vaccination within 1 month immunization Flubio .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Flubio Vaccine ( Influenza HA )</keyword>
	<keyword>Infants</keyword>
	<keyword>Children</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>